LivaNova PLC
NASDAQ:LIVN
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
UK |
LivaNova PLC
NASDAQ:LIVN
|
3.4B USD | 2.7 | ||
US |
Abbott Laboratories
NYSE:ABT
|
182.6B USD | 4.8 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
132.5B USD | 9.6 | ||
US |
Stryker Corp
NYSE:SYK
|
123.5B USD | 6.5 | ||
IE |
Medtronic PLC
NYSE:MDT
|
107.2B USD | 2.1 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
104.5B USD | 5.5 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
67.6B USD | 2.7 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
57.2B EUR | 3.2 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
51.1B USD | 7.2 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.4B CNY | 10 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
50B USD | 22.3 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.